(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 39.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Travere Therapeutics's revenue in 2025 is $273,533,000.On average, 7 Wall Street analysts forecast TVTX's revenue for 2025 to be $35,037,319,308, with the lowest TVTX revenue forecast at $29,645,712,393, and the highest TVTX revenue forecast at $39,411,578,228. On average, 7 Wall Street analysts forecast TVTX's revenue for 2026 to be $48,856,681,061, with the lowest TVTX revenue forecast at $39,980,817,112, and the highest TVTX revenue forecast at $60,032,145,773.
In 2027, TVTX is forecast to generate $66,264,023,876 in revenue, with the lowest revenue forecast at $54,981,726,968 and the highest revenue forecast at $80,883,517,039.